

September 8, 2020



# Cocrystal Pharma to Present at the H.C. Wainwright 22nd Annual Global Investment Conference

– Live video webcast with Chairman and CEO, Dr. Gary Wilcox, on Monday, September 14<sup>th</sup> at 3:30 PM EDT –

**BOTHELL, WA, Sept. 08, 2020 (GLOBE NEWSWIRE) --** [Cocrystal Pharma, Inc.](#) (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics, today announced that Dr. Gary Wilcox, Chairman and Chief Executive Officer of Cocrystal, will present at [H.C. Wainwright 22<sup>nd</sup> Annual Global Investment Conference](#) on Monday, September 14, 2020 at 3:30 PM EDT.

In addition to the presentation, management will also be available to participate in virtual one-on-one meetings with qualified members of the investor community who are registered to attend the conference. For more information, please visit the conference website [here](#).

A [live video webcast](#) of the presentation will be available on the [IR Calendar](#) page of the [Investors](#) section of the Company’s website ([cocrystalpharma.com](#)). The video webcast replay will be made available two hours following the event.

## About Cocrystal Pharma, Inc.

Cocrystal Pharma, Inc. is a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, SARS-CoV-2 virus, hepatitis C viruses, and norovirus infections. Cocrystal employs unique structure-based technologies and Nobel Prize winning expertise to create first- and best-in-class antiviral drugs. For further information about Cocrystal, please visit [www.cocrystalpharma.com](#).

## Investor and Media Contact:

JTC Team, LLC  
(833) 475-8247  
[COCP@jtcir.com](mailto:COCP@jtcir.com)

###



Source: Cocrystal Pharma, Inc.